Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the safety and efficacy, measured as best objective response rate (BORR), of MDX-010 when administered in combination with a gp100 melanoma peptide vaccine and to demonstrate the independent contributions of the vaccine and MDX-010 when given to patients with unresectable Stage III or IV melanoma who have been previously treated with other agents.
Critère d'inclusion
- HLA-A*0201-Positive Patients with Previously Treated, Unresectable Stage III or IV Melanoma